公开(公告)号：US20220125884A1

公开(公告)日：2022-04-28

申请号：US17506483

申请日：2021-10-20

申请人： Gilead Sciences, Inc.

发明人： Manuel Baca ,  Sarah A. Gilmore ,  Magdeleine S. Hung ,  Hassan Javanbakht ,  Manu Kanwar ,  Shahzada Khan ,  Prasenjit K. Mukherjee ,  Mark R. Nagel ,  Giuseppe Papalia ,  Danny W. Tam ,  Majlinda K. Thomas

IPC分类号： A61K38/20 ,  C07K14/55 ,  A61P31/20 ,  A61P35/00 ,  A61K39/395

摘要： Provided are serum half-life extended-IL-2 variant (IL-2v) heterodimers having reduced binding to the IL2Rα (CD25) subunit. In particular, Fc-IL-2v heterodimers are provided and methods for making and using, e.g. for enhancing an immune response, e.g. in the prevention and treatment of viral infections and cancer.

公开(公告)号：US11896648B2

公开(公告)日：2024-02-13

申请号：US17506483

申请日：2021-10-20

申请人： Gilead Sciences, Inc.

发明人： Manuel Baca ,  Sarah A. Gilmore ,  Hassan Javanbakht ,  Prasenjit K. Mukherjee

IPC分类号： A61K38/20 ,  A61P35/00 ,  A61K39/395 ,  C07K14/55 ,  A61K38/00 ,  A61P31/20

CPC分类号： A61K38/2013 ,  A61K39/3955 ,  A61P31/20 ,  A61P35/00 ,  C07K14/55 ,  A61K38/00 ,  C07K2319/30

摘要： Provided are serum half-life extended-IL-2 variant (IL-2v) heterodimers having reduced binding to the IL2Rα (CD25) subunit. In particular, Fc-IL-2v heterodimers are provided and methods for making and using, e.g. for enhancing an immune response, e.g. in the prevention and treatment of viral infections and cancer.

公开(公告)号：US20240269235A1

公开(公告)日：2024-08-15

申请号：US18540652

申请日：2023-12-14

申请人： Gilead Sciences, Inc.

发明人： Manuel Baca ,  Sarah A. Gilmore ,  Magdeleine S. Hung ,  Hassan Javanbakht ,  Manu Kanwar ,  Shahzada Khan ,  Prasenjit K. Mukherjee ,  Mark R. Nagel ,  Giuseppe Papalia ,  Danny W. Tam ,  Majlinda K. Thomas

IPC分类号： A61K38/20 ,  A61K38/00 ,  A61K39/395 ,  A61P31/20 ,  A61P35/00 ,  C07K14/55

CPC分类号： A61K38/2013 ,  A61K39/3955 ,  A61P31/20 ,  A61P35/00 ,  C07K14/55 ,  A61K38/00 ,  C07K2319/30

摘要： Provided are serum half-life extended-IL-2 variant (IL-2v) heterodimers having reduced binding to the IL2Rα (CD25) subunit. In particular, Fc-IL-2v heterodimers are provided and methods for making and using, e.g. for enhancing an immune response, e.g. in the prevention and treatment of viral infections and cancer.

公开(公告)号：US20240254118A1

公开(公告)日：2024-08-01

申请号：US18391258

申请日：2023-12-20

申请人： Gilead Sciences, Inc.

发明人： Megan K. Armstrong ,  Elbert Chin ,  Chienhung Chou ,  Laurent P. Debien ,  Joshua D. Farr ,  Pancham Lal Gupta ,  Chao-I Hung ,  Michael L. Mitchell ,  Prasenjit K. Mukherjee ,  Shaina V. Nguyen ,  Gregory T. Notte ,  Daniel Roa ,  Adam J. Schrier ,  Zheng-Yu Yang

IPC分类号： C07D471/04 ,  A61K31/473 ,  A61K31/4741 ,  A61K31/4743 ,  A61K31/4745 ,  A61K31/4748 ,  A61K31/496 ,  A61K31/501 ,  A61K31/506 ,  A61K31/5355 ,  A61K31/5377 ,  A61K31/5386 ,  A61K31/541 ,  A61K31/55 ,  C07D401/12 ,  C07D491/048 ,  C07D513/04 ,  C07D519/00

CPC分类号： C07D471/04 ,  A61K31/473 ,  A61K31/4741 ,  A61K31/4743 ,  A61K31/4745 ,  A61K31/4748 ,  A61K31/496 ,  A61K31/501 ,  A61K31/506 ,  A61K31/5355 ,  A61K31/5377 ,  A61K31/5386 ,  A61K31/541 ,  A61K31/55 ,  C07D401/12 ,  C07D491/048 ,  C07D513/04 ,  C07D519/00

摘要： The present disclosure relates generally to compounds that inhibit PRMT5. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through inhibiting PRMT5. The disclosure further relates to the use of the compounds for the treatment of a disease or condition associated with chromosome 9p21 deletion or MTAP null. The disclosure further relates to the use of the compounds for the treatment of cancers.